Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

surufatinib × Endocrine × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3 Thoracic 1 NET 1 Gynecologic 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Magnetic Resonance Spectroscopy 16 Specimen Handling 14 lutetium Lu 177 dotatate 13 Everolimus 9 pembrolizumab 8 Nivolumab 6 gallium Ga 68 dotatate 5 cabozantinib 5 lenvatinib 4 atezolizumab 4 X-Rays 4 Ipilimumab 4 pasireotide 3 Octreotide 3 Immunoglobulin G 3 Fluorodeoxyglucose F18 3 Etoposide 3 Disulfides 3 Cisplatin 3 Carboplatin 3 Bevacizumab 3 trametinib 2 lanreotide 2 fluorodopa F 18 2 entrectinib 2 durvalumab 2 dabrafenib 2 copper dotatate CU-64 2 cobimetinib 2 Vemurafenib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07272512 2025-12-19

ZSPAC-17

Shanghai Zhongshan Hospital

Phase 4 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡